Synchron

Synchron is a neurotechnology company developing the Stentrode, a Brain–computer interface built into a vascular stent and delivered through the jugular to a vein on the surface of the motor cortex, so that no craniotomy is needed. Founded in Melbourne in 2012 and now headquartered in New York, it began implanting patients in Australia in 2019 and in the United States in 2022. It has pursued a deliberately low-bandwidth strategy, in contrast to competitors chasing channel count.

§Overview

The company's strategic premise is that BCI deployment is limited less by the number of neurons recorded than by the willingness of surgeons, regulators and patients to accept an implant. Open-skull electrode arrays require neurosurgery, carry infection and haemorrhage risk, and are performed at a small number of centres. Endovascular delivery, by contrast, is a procedure that interventional neuroradiologists already perform thousands of times a year for stroke and aneurysm, using equipment that most large hospitals already have. The argument is explicitly modelled on the diffusion of the Cochlear implant and of Deep brain stimulation, both of which reached large patient populations only once the implantation procedure became routine.

The price of that choice is signal. The Stentrode carries sixteen electrodes inside a vessel wall, separated from cortex by the vessel and by tissue, and it records local field potentials rather than single-unit activity. It cannot approach the information rate of a penetrating array. Synchron's position is that a small, reliable set of control signals is enough for the applications that matter first: switch control, cursor movement, and communication for people with severe paralysis.

§History

Thomas Oxley, a neurologist, and Nicholas Opie, a biomedical engineer, developed the endovascular approach at the University of Melbourne with support from Australian and United States defence research funding. Their starting observation was that veins run close to the cortical surface and that stents are routinely delivered to them. A stent could therefore carry electrodes and, over weeks, become endothelialized into the vessel wall, which would stabilize the recording. The group's 2016 report of chronic cortical recordings from a stent-mounted array in freely moving sheep established that the approach could work at all.¹

The SWITCH trial implanted the device in four Australian patients with severe paralysis, mostly from amyotrophic lateral sclerosis. The first-in-human report described patients using the system for digital device control at home,² and a subsequent safety analysis found no device-related serious adverse events and no vessel occlusion at twelve months.³ Synchron then received a United States investigational device exemption and began the COMMAND early feasibility study, implanting its first American patient at Mount Sinai in 2022. COMMAND enrolled a small cohort across several centres and has been reported as meeting its primary safety endpoint.

1. 2012
   Founded
   Thomas Oxley and Nicholas Opie establish the company in Melbourne around an endovascular electrode concept developed with defence research funding.
2. 2016
   Animal validation
   Recordings from a stent-mounted array in sheep demonstrate that a vessel-borne electrode can pick up cortical signals over months.
3. 2019-2021
   SWITCH trial
   Four Australian patients with severe paralysis receive the device; the trial reports vessel patency and usable control signals at twelve months.
4. 2021
   US regulatory clearance to trial
   The FDA grants an investigational device exemption, permitting the first US implants.
5. 2022-2024
   COMMAND
   A small US early feasibility study across several centres reports acceptable safety and functional digital control.
6. 2025
   Platform integrations
   Apple's accessibility framework adds native support for BCI input with Synchron as a partner, and the company announces work with NVIDIA on decoding models.

§Technology

The device is a self-expanding nitinol stent with electrodes mounted on its struts. A catheter carries it through the jugular vein into the superior sagittal sinus, the large vein running along the midline above the motor cortex, where it is deployed so that the electrodes press against the vessel wall next to motor cortex, whose leg representation lies nearest the midline. Over several weeks the stent endothelializes and becomes incorporated into the vessel wall. That stabilizes it mechanically and, Synchron argues, reduces the chronic foreign-body response that degrades penetrating array signals over years.

A lead runs down the vein to a subclavian transmitter unit implanted in the chest, which powers the array and relays data wirelessly. The architecture is closer to a pacemaker than to a research rig, a design choice shared with most deployed Neuroprosthetics. The system decodes attempted movements, typically of a foot or ankle, into discrete switch events that are mapped onto interface actions. It delivers no stimulation, so the device provides no sensory feedback and is not a bidirectional interface.

The recording site sets the signal ceiling. The device picks up local field potentials, not the spike trains that Neural decoding work on penetrating arrays exploits, which limits the system to a small number of distinguishable commands. The resulting interaction resembles switch scanning more than continuous multi-degree-of-freedom control. Stentrode sets out the mechanism in full.

The tradeoff stated plainly

A Utah array records individual neurons and supports high-dimensional control, at the cost of a craniotomy and progressive signal loss from glial scarring. The Stentrode records population activity through a vessel wall and supports a handful of commands, but needs no craniotomy and offers a stable interface. Which is the better device depends entirely on how many patients would accept brain surgery, a question the field has not answered empirically.

§Partnerships and funding

Synchron has raised venture funding from investors including ARCH Venture Partners, with participation reported from vehicles associated with Jeff Bezos and Bill Gates. It has pursued integration partnerships instead of building its own application layer. These include a demonstration of Amazon Alexa control and, in 2025, participation in Apple's addition of a native brain-computer interface input protocol to its accessibility framework. That was the first time a major consumer platform treated neural input as a first-class modality alongside touch and switch control. A separate collaboration with NVIDIA concerns machine-learning models for decoding, built on the accumulated recordings from its trial participants.

The platform strategy has a larger consequence than it first appears to. A BCI that presents itself to an operating system as a standard input device inherits every application already written for accessibility, which takes a substantial part of the software problem out of the company's own scope.

§Reception

Clinical reception has been favourable on safety, which is the metric an early feasibility study is designed to address. Independent commentators have noted that endovascular delivery does lower the barrier to implantation, and that the reported vessel patency results are the most important finding, since thrombosis in a major cerebral vein would be a catastrophic failure.

Criticism concentrates on capability. Sixteen channels of field potential cannot support the speech decoding results that electrocorticographic and penetrating arrays have produced, and cannot approach the cursor performance demonstrated by BrainGate participants. Some researchers argue that the company is solving the wrong constraint, because patients with locked-in syndrome will accept a craniotomy and the value of a BCI rises steeply with bandwidth. Synchron counters that the field has produced two decades of impressive results in a few dozen research participants and almost no deployed devices, and that reaching many patients requires a procedure ordinary hospitals can perform.

Comparison with Neuralink is unavoidable and of limited use, since the two companies occupy different points on the same tradeoff curve. Neuralink's robot-inserted thread arrays record far more channels and require skull penetration; Synchron's device records far fewer and does not. Both remain in early clinical studies, and neither has an approved product.

§Outlook

The decisive question is whether a pivotal trial can demonstrate benefit against an endpoint a regulator accepts. Early feasibility studies establish safety in a handful of patients. Approval requires a defined patient population, a validated outcome measure and a comparator, and the BCI field has settled none of these. Synchron has said it intends to run a larger trial, and the design of that trial will show what claim the company believes it can support.

The second question is durability. Endothelialization stabilizes the device but also fixes it permanently in a vessel. Explantation has not been demonstrated in humans, and the long-term consequences of a foreign body sitting in a major cerebral sinus for decades are unknown.

The third is governance. The Neurorights campaign and the Mental privacy literature both concern who owns neural recordings and what may be inferred from them, and a device that streams cortical signals to a consumer operating system sits directly in the path of that argument. Field potentials from motor cortex are crude by the standards of what laboratory decoding work can extract, but that offers only weak reassurance, because in this field inference from neural data has consistently outrun what the raw signal appears to contain. Synchron's own strategy assumes that the bandwidth ceiling limiting the device also limits the Human–AI merger ambitions behind much BCI investment; its competitors dispute this.

§See also

• Stentrode
• Brain–computer interface
• Neuralink
• Utah array
• Electrocorticography interfaces
• Neural decoding
• Speech neuroprosthesis
• Neurorights

§References